Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz, Jonathan J. Havel, Vladimir Makarov et al. · Cell · 2017
Cited by 2,379 works. doi:10.1016/j.cell.2017.09.028 Open-access PDF
Authors
- Nadeem Riaz
- Jonathan J. Havel
- Vladimir Makarov
- Alexis Desrichard
- Walter John Urba
- Jennifer S. Sims
- Frank Stephen Hodi
- Salvador Martín‐Algarra
- Rajarsi Mandal
- William Howard Sharfman
- Shailender Bhatia
- Wen‐Jen Hwu
- Thomas Frank Gajewski
- Craig Lee Slingluff
- Diego Chowell
- Sviatoslav M. Kendall
- Han Chang
- Rachna Shah
- Fengshen Kuo
- Luc G.T. Morris
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- STAR: ultrafast universal RNA-seq aligner
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation